Skip to main content

Table 1 Baseline characteristics of study population

From: Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19

Characteristic

Total

(n = 3,788)

Hypertension

(n = 1,190)

Non-hypertension (n = 2,598)

P-value

Age (yr)

52.1 ± 15.1

63.9 ± 14.0

46.7 ± 12.3

< 0.001

Age distribution (yr)

   

< 0.001

30‒39

970 (25.6)

57 (4.8)

913 (35.1)

 

40‒49

860 (22.7)

142 (11.9)

718 (27.6)

 

50‒59

808 (21.3)

259 (21.8)

549 (21.1)

 

60‒69

570 (15.0)

289 (24.3)

281 (10.8)

 

70‒79

374 (9.9)

271 (22.8)

103 (4.0)

 

80–89

180 (4.8)

151 (12.7)

29 (1.1)

 

≥ 90

26 (0.7)

21 (1.8)

5 (0.2)

 

Male sex

1,692 (44.7)

605 (50.8)

1,087 (41.8)

< 0.001

Comorbidity

    

Diabetes

655 (17.3)

483 (40.6)

172 (6.6)

< 0.001

Dyslipidemia

1,103 (29.1)

716 (60.2)

387 (14.9)

< 0.001

Chronic kidney disease

234 (6.2)

213 (18.0)

21 (0.8)

< 0.001

Chronic obstructive pulmonary disease

387 (10.2)

213 (18.0)

174 (6.7)

< 0.001

Cancer

313 (8.3)

153 (12.9)

160 (6.2)

< 0.001

Cardiovascular disease

513 (13.5)

429 (36.1)

84 (3.2)

< 0.001

Ischemic heart disease

269 (7.1)

226 (19.0)

43 (1.7)

< 0.001

Myocardial infarction

36 (1.0)

34 (2.9)

2 (0.1)

< 0.001

Stroke

185 (4.9)

163 (13.7)

22 (0.8)

< 0.001

Congestive heart failure

223 (5.9)

191 (16.1)

32 (1.2)

< 0.001

  1. Data are presented as mean ± standard deviation or number (%)